Influence of PI3K/AKT pathway on imatinib mesylate treatment outcome in chronic myeloid leukemia patients

被引：0
|
作者：
Banapuram, Swathi [1 ]
Gorre, Manjula [1 ]
Digumarti, Raghunadha Rao [2 ]
Satti, Vishnupriya [1 ]
Palle, Komaraiah [3 ]
Annamaneni, Sandhya [3 ,4 ]
机构：
[1] Osmania Univ, Hyderabad, Telangana, India
[2] Homi Bhabha Canc Hosp & Res Ctr, Visakhapatnam, Andhra Pradesh, India
[3] Texas Tech Univ, Hlth Sci Ctr, Lubbock, TX 79430 USA
[4] Osmania Univ, Dept Genet, Hyderabad, Telangana, India
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-4682
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4682
引用
收藏
页数：2
相关论文
共 50 条
  • [21] The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia
    Eskazan, Ahmet Emre
    Elverdi, Tugrul
    Yalniz, Fevzi Firat
    Salihoglu, Ayse
    Ar, Muhlis Cem
    Aydin, Seniz Ongoren
    Baslar, Zafer
    Aydin, Yildiz
    Tuzuner, Nukhet
    Ozbek, Ugur
    Soysal, Teoman
    LEUKEMIA & LYMPHOMA, 2014, 55 (12) : 2935 - 2937
  • [22] Imatinib mesylate - The new gold standard for treatment of chronic myeloid leukemia
    Peggs, K
    Mackinnon, S
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (11): : 1048 - 1050
  • [23] Treatment modalities in hematology: Imatinib mesylate as therapy for chronic myeloid leukemia
    A. Gratwohl
    International Journal of Hematology, 2002, 76 : 149 - 149
  • [24] Treatment modalities in hematology: Imatinib mesylate as therapy for chronic myeloid leukemia
    Gratwohl, A
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2002, 76 (Suppl 1) : 149 - 149
  • [25] Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate
    Zonder J.A.
    Schiffer C.A.
    Current Hematologic Malignancy Reports, 2006, 1 (3) : 141 - 151
  • [26] TRIM22 knockdown suppresses chronic myeloid leukemia via inhibiting PI3K/Akt/mTOR signaling pathway
    Li, Liyin
    Qi, Yanhua
    Ma, Xiaobo
    Xiong, Guosheng
    Wang, Lijun
    Bao, Cuixia
    CELL BIOLOGY INTERNATIONAL, 2018, 42 (09) : 1192 - 1199
  • [27] Effects of Twist1 on drug resistance of chronic myeloid leukemia cells through the PI3K/AKT signaling pathway
    Yuan, Ruilan
    Chang, Jin
    He, Jianxia
    CELLULAR AND MOLECULAR BIOLOGY, 2020, 66 (06) : 81 - 85
  • [28] Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase
    Kiguchi, Toru
    Tauchi, Tetsuzo
    Ito, Yoshikazu
    Miyazawa, Keisuke
    Kimura, Yukihiko
    Ohyashiki, Kazuma
    LEUKEMIA RESEARCH, 2009, 33 (03) : 506 - 508
  • [29] PTEN Regulated BCRP/ABCG2 and Side Population Through PI3K/Akt Pathway In Chronic Myeloid Leukemia
    Huang, Fang-Fang
    Zhang, Li
    Yu, Yan-Hui
    Chen, Fang-ping
    Zeng, Hui
    Niu, Ting
    Wu, Deng-shu
    BLOOD, 2013, 122 (21)
  • [30] PTEN Regulates BCRP/ABCG2 and the Side Population through the PI3K/Akt Pathway in Chronic Myeloid Leukemia
    Huang, Fang-Fang
    Zhang, Li
    Wu, Deng-Shu
    Yuan, Xiao-Yu
    Chen, Fang-Ping
    Zeng, Hui
    Yu, Yan-Hui
    Zhao, Xie-Lan
    PLOS ONE, 2014, 9 (03):
12345